Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754991 | 0.77 | TAAR1 (0.39) | CTRB1FASNGRM2SLC6A2SLC6A4 | |
| SCHEMBL746094 | 0.77 | CTRB1 (0.35) | CTRB1FASNGRM2GBA1 | |
| SCHEMBL3972137 | 0.77 | CTRB1 (0.35) | CTRB1FASN | |
| SCHEMBL17512439 | 0.76 | CALM1 (0.39) | CTRB1FASNGRM2GBA1F2 | |
| SCHEMBL16398868 | 0.76 | TP53 (0.41) | CTRB1FASN | |
| SCHEMBL7703226 | 0.74 | KDM4E (0.35) | CTRB1FASNTAAR1 | |
| SCHEMBL6076922 | 0.74 | TSHR (0.40) | CTRB1FASNGRM2GBA1F2 | |
| SCHEMBL201288 | 0.74 | HTT (0.39) | CTRB1FASN | |
| SCHEMBL699638 | 0.74 | CTRB1 (0.33) | CTRB1FASNGRM2GBA1F2 | |
| SCHEMBL230546 | 0.73 | CTRB1 (0.36) | CTRB1FASNGRM2F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | CTRB1 744/4885FASN 99/4885IDO1 434/4885 |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | CTRB1 2288/4885FASN 1905/4885IDO1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.